|View printer-friendly version|
Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel
“John’s appointment comes at a critical time for Portola, as we execute on the successful launch of our first medicine Bevyxxa (betrixaban), and continue to advance our two other lead development programs, andexanet alfa and cerdulatinib, through key clinical and regulatory milestones,” said Mr. Lis. “His extensive legal and business expertise, as well as his leadership track record, will be invaluable in addressing the complex issues that accompany our transition into a global commercial organization, and we are thrilled to welcome John to the team.”
Mr. Moriarty joins Portola from
"Portola has made substantial and rapid progress in its commercial evolution and I am excited to join the team at such a pivotal time,” said Mr. Moriarty. “Portola has a well-recognized, science-based culture and I look forward to working alongside such a talented and passionate team to deliver new medicines that have the potential to transform patient care in the fields of thrombosis and hematology.”
Mr. Moriarty received his J.D. from the
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.